Nachrichten zur Quest Diagnostics Aktie

BCAL Commences US Operations

BCAL Diagnostics Limited (ASX: BDX) (“BCAL” or “the Company”) is pleased to announce that it has established a North Carolina,…

Quest Diagnostics Expands in North America With New Acquisition

DGX acquires 100% of LifeLabs from OMERS, at approximately $1 billion. It will help LifeLabs to improve healthcare for Canadians.…

Quest Diagnostics (DGX) New Deal Aids Diagnostic Access in Ohio

Quest Diagnostics (DGX) signs an agreement to acquire select assets of University Hospitals outreach laboratory services business.…

Quest Diagnostics (DGX) Debuts Micronutrient Deficiency Panels

Quest Diagnostics (DGX) introduces 13 blood tests to identify micronutrient deficiencies.…

Quest Diagnostics (DGX) New Study Exposes Alarming Data on STI

Quest Diagnostics (DGX) joint study with the University of Alabama finds pregnant women undertested for STIs, raising serious concerns on…

Quest Diagnostics stock hits 52-week high at $151.94 By Investing.com

Quest Diagnostics stock hits 52-week high at $151.94…

Quest Diagnostics (DGX) Gains From Innovation, Customer Wins

A key driver in Brain Health growth is Quest Diagnostics (DGX) Alzheimers disease portfolio, featuring the AD-Detect blood testing services…

Should Quest Diagnostics (DGX) be in Your Portfolio Now?

Quest Diagnostics (DGX) robust base business performance instills optimism for long-term growth.…

Quest Diagnostics (DGX) Haystack Oncology Forges New MRD Deal

Quest Diagnostics (DGX) subsidiary, Haystack Oncology, partners on the use of its MRD technology.…

Quest Diagnostics (DGX) Q2 Earnings and Revenues Top Estimates

Quest Diagnostics (DGX) delivered earnings and revenue surprises of 1.73% and 0.50%, respectively, for the quarter ended June 2024. Do…

Quest Diagnostics: On A Quest For Growth

…

What Awaits Quest Diagnostics (DGX) in Q2 Earnings Release?

Quest Diagnostics (DGX) is likely to have maintained its robust base business performance in the second quarter of 2024. However,…

Quest Diagnostics to acquire certain assets from OhioHealth

…

Global Precision Diagnostics Market Size To Worth USD 254.48 Billion By 2033 | CAGR Of 13%

The Global Precision Diagnostics Market Size was Valued at USD 74.98 Billion in 2023 and the Worldwide Precision Diagnostics Market…

Quest Diagnostics (DGX) to Expand in Canada With LifeLabs Buyout

By integrating LifeLabs into its operations, Quest Diagnostics (DGX) aims to enhance the accessibility and quality of diagnostic services for…

Global PCOS Diagnostic Market Size To Exceed USD 6.1 Billion By 2033 | CAGR Of 5.18%

The Global PCOS Diagnostic Market Size was Valued at USD 3.68 Billion in 2023 and the Worldwide PCOS Diagnostic Market…

Is It Apt to Hold Quest Diagnostics (DGX) Stock for Now?

Strength in the core business bodes well for Quest Diagnostics (DGX). However, mounting debt levels and reduced COVID-19 testing revenues…

PTA-News: Small- & MicroCap Investment: KI als Wachstumsmotor: CrowdStrike, Adcore, Quest Diagnostics

DJ PTA-News: Small- & MicroCap Investment: KI als Wachstumsmotor: CrowdStrike, Adcore, Quest Diagnostics Unternehmensmitteilung für den Kapitalmarkt Frankfurt (pta/23.06.2024/10:00) -…

Quest Diagnostics (DGX) Gains From New M&As Amid Competition

In Physician Lab Services, Quest Diagnostics (DGX) is benefiting from the broad-based return to care, overall market growth and share…

Quest Diagnostics (DGX) New Buyout Ramps Up Cancer Diagnosis

Quest Diagnostics (DGX) completes the acquisition of PathAI Diagnostics, accelerating the adoption of AI and digital pathology to improve cancer…

Analyst Report: Quest Diagnostics, Inc.

…

Quest Diagnostics said to be nearing deal for Canadas Lifelabs

…

Kaum Impulse für die Quest Diagnostics-Aktie (127,3380 €)

Wenig Kursbewegung aktuell bei der Aktie von Quest Diagnostics . Der jüngste Kurs betrug 136,84 US-Dollar. Die Wertschätzung der Börsenteilnehmer…

Quest Diagnostics: Lets Keep Waiting

…

Quest Diagnostics (DGX) Grows in Digital Pathology With New Deal

Quest Diagnostics (DGX) pathology laboratories nationwide are set to get a boost with PathAIs AISight digital pathology image management system.…

Quest Diagnostics (DGX) Inks Deal to Acquire PathAI Diagnostics

Quest Diagnostics (DGX) latest transaction combines its oncology expertise and scale with PathAIs AI and digital pathology innovations.…

Quest Diagnostics (DGX) Q1 Earnings Top Estimates, Margins Down

Quest Diagnostics (DGX) continues its strong momentum of base business revenue growth in the first quarter of 2024.…

Minimale Kursveränderung bei Quest Diagnostics-Aktie (120,7245 €)

CODE Das Wertpapier notiert aktuell bei 128,30 US-Dollar. Kaum auffällig ist derzeit an der Börse der Kurs von Quest Diagnostics.…

Quest Diagnostics (DGX) to Post Q1 Earnings: Whats in Store?

Acquisitions and partnerships with health plans are expected to drive Quest Diagnostics (DGX) base business performance in the first quarter…

Quest Diagnostics (DGX) Collaborates With Broad Clinical Labs

Quest Diagnostics (DGX) collaboration is intended to demonstrate the clinical value of WGS as a first-line genetic test for postnatal…

Analyst Report: Quest Diagnostics, Inc.

…

Quest Diagnostics (DGX) Hurt by Lower Testing Sales, Competition

Quest Diagnostics (DGX) faces intense competition, primarily from LabCorp as well as other commercial laboratories and hospitals.…

Quest Diagnostics (DGX) Boosts Oncology Portfolio With New Test

Quest Diagnostics (DGX) debuts the MelaNodal Predict test in collaboration with SkylineDx.…

Quest Diagnostics (DGX) Debuts PFAS Blood Test Offering

Quest Diagnostics (DGX) introduces the first consumer-initiated blood test with physician consult on questhealth.com.…

Reasons to Retain Quest Diagnostics (DGX) Stock for Now

Strength of the base business bodes well for Quest Diagnostics (DGX).…

Earnings call: Quest Diagnostics sees robust growth and AI investment By Investing.com

Earnings call: Quest Diagnostics sees robust growth and AI investment…

Quest Diagnostics-Aktie heute am Aktienmarkt kaum gefragt: Kurs fällt (116,0444 €)

Im Minus liegt derzeit die Aktie von Quest Diagnostics . Das Papier kostete zuletzt 126,16 US-Dollar. Im US-amerikanischen Wertpapierhandel hat…

Quest Diagnostics Inc. (DGX) Q4 2023 Earnings Call Transcript

…

Quest Diagnostics (DGX) Q4 Revenues Top, Gross Margin Down

Quest Diagnostics (DGX) delivers better-than-expected earnings and revenues in the fourth quarter of 2023.…

Quest Diagnostics (DGX) Q4 Earnings and Revenues Beat Estimates

Quest Diagnostics (DGX) delivered earnings and revenue surprises of 0.47% and 1.80%, respectively, for the quarter ended December 2023. Do…

Quest Diagnostics (DGX) Advances in Cancer Research With New Deal

Quest Diagnostics (DGX) subsidiary Haystack Oncology collaborates with TriSalus Life Sciences to improve therapeutic options for aggressive forms of cancer.…

3 Discounted MedTech Stocks Poised for Sturdy Growth in 2024

Prestige Consumer Health (PBH), Quest Diagnostics (DGX) and Hologic (HOLX) are currently at discounted zone that are expected to provide…

Quest Diagnostics (DGX) and Fitbit Team Up for New Pilot Study

Quest Diagnostics (DGX) partners with Fitbit to study the potential of wearable devices to improve metabolic health.…

Quest Diagnostics (DGX) to Post Q4 Earnings: Whats in Store?

Quest Diagnostics (DGX) fourth-quarter 2023 results are likely to reflect the robust strength of its base business.…

Quest Diagnostics (DGX) Inks New Deal With Ultima Genomics

Quest Diagnostics (DGX) new partnership is likely to leverage its oncology expertise and national scale.…

Quest Diagnostics (DGX) to Boost Lab Services With New Buyout

Quest Diagnostics (DGX) recent acquisition seeks to increase accessibility to cutting-edge, high-caliber and reasonably priced laboratory services.…

Reasons to Retain Quest Diagnostics (DGX) Stock for Now

Investors are optimistic about Quest Diagnostics (DGX) on strength in base business and strategic collaborations.…

Quest Diagnostics (DGX) Unveils the 88-Compound NPS Test Panel

Quest Diagnostics (DGX) launches the new 88-Compound NPS test panel to address the changing drug epidemic.…

Quest Diagnostics (DGX) Haystack Oncology Inks New Deal

Quest Diagnostics (DGX) wholly owned subsidiary, Haystack Oncology, partners with the Rutgers Cancer Institute of New Jersey.…

Quest Diagnostics (DGX) & CDC to Assess Hepatitis C Burden

Quest Diagnostics (DGX) and CDC expand research collaboration to better understand the Hepatitis C burden in the United States.…